Ernexa Therapeutics (ERNAW) Non-Current Debt (2013 - 2023)

Ernexa Therapeutics (ERNAW) has 10 years of Non-Current Debt data on file, last reported at $768000.0 in Q1 2023.

• Quarterly Non-Current Debt changed N/A year-over-year to $768000.0 in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $768000.0 (changed N/A YoY) and the FY2022 annual result came in at $1.2 million, changed N/A from the prior year.
• Non-Current Debt slipped to $768000.0 in Q1 2023, from $1.2 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $2.8 million in Q4 2019 to a low of $532000.0 in Q4 2020.
• A 4-year average of $1.7 million and a median of $1.8 million in 2019 frame the typical range for Non-Current Debt.
• Annual changes were most pronounced in 2019 — Non-Current Debt grew 0.77% — and 2020, when it tumbled 80.65%.
• Tracing ERNAW's Non-Current Debt over 4 years: stood at $2.8 million in 2019, then plunged by 80.65% to $532000.0 in 2020, then soared by 126.69% to $1.2 million in 2022, then plunged by 36.32% to $768000.0 in 2023.
• The last three Non-Current Debt figures came in at $768000.0 (Q1 2023), $1.2 million (Q4 2022), and $532000.0 (Q4 2020), per Business Quant data.